Advertisement

Picture [LSG] Life-Sciences-Germany.com Ė The Business Web Portal 600x80px
Document › Details

Horizon Discovery Group plc. (6/1/17). "Press Release: ATUM and Horizon Discovery Announce Collaboration and Technology Cross-License to Simplify and Speed Bioproduction Cell Line Development". Newark, CA & Cambridge.

Organisations Organisation Horizon Discovery Group plc (LSE: HZD)
  Group Horizon Discovery (Group)
  Organisation 2 ATUM (US)
  Group ATUM (Group)
Products Product cell line development (research assays)
  Product 2 vector (biotech)
Persons Person Disley, Darrin M. (Horizon Discovery 201109 CEO before Commercial Director)
  Person 2 Minshull, Jeremy (ATUM / DNA2.0 201706 CEO + Co-Founder)
     


> Horizonís CHO SOURCE Platform now incorporates exclusive ATUM vectors as standard

> ATUM has licensed Horizonís CHO SOURCE platform to offer cell line development services with its Leap-In Transposase Technology


ATUM (formerly DNA2.0, Inc.) and Horizon Discovery (LSE: HZD) (ďHorizonĒ), the world leader in the application of gene editing technologies, today announced they have signed a cross-license agreement for Horizonís CHO SOURCE platform and ATUMís vector technology to speed development of highly productive stable cell lines for drug development.

ATUM has licensed Horizonís CHO SOURCE platform, including the Glutamine Synthetase (GS) Knock-Out CHO K1 (Chinese hamster ovary) line, and will use its proprietary Leap-In® Transposase Technology to offer cell line development services. Horizon has exclusively licensed a vector suite developed by ATUM for the CHO SOURCE platform, to provide a complete cell line solution to its customers. Together, these technologies enable expression of complex biologics for customers of both ATUM and Horizon. ATUM is also offering Horizon customers a no-fee evaluation license for the transposase system.

The CHO SOURCE platform increases stringency of selection as compared with historical platforms based around chemical inhibition such as Methionine Sulphoximine (MSX) and Methotrexate (MTX). The result is more rapid identification of clones expressing a biotherapeutic product at industry-relevant levels. CHO SOURCE is a commercially disruptive platform based on a one-time fee for access for full commercial use.

The Horizon GS knockout cell line has been developed specifically to address the growing needs of biotech companies and CMOs in biological manufacturing. As part of the CHO SOURCE Platform, this fully traceable and GMP banked line is specifically designed for customers who want to rapidly implement an improved solution but without sacrificing time or putting quality at risk.

ATUMís vector suite has been developed as part of a partnership with Horizon. These novel vectors are comprised of a mammalian expression technology that has been combined with additional elements that improve aspects of the protein production pathway. They have been designed for ease of use, with dual or single promoter options available as part of the CHO SOURCE platform. In tandem with a powerful selection system, these vectors will drive the generation of high yield stable cell lines.

Since receiving the first patent for Leap-In, ATUMís transposon and tranposase-based tool, in September 2016, the technology has been licensed by several companies in the biotechnology and pharmaceutical industries where it has demonstrated the generation of multi gram/L stable pools. The technology can be accessed through ATUMís cell line development service, which now combines Leap-In with the CHO SOURCE platform, or by evaluating the LeapIn transposase together with the CHO SOURCE platform for internal development followed by licensing the two technologies separately.

"Horizonís GS line and ATUMís vectors and transposase technology are a very powerful combination for production of stable cell lines in industry-leading timelines,Ē said Jeremy Minshull, co-founder and CEO of ATUM. ďThis technology is suited not just for regular antibodies, but for the next wave of biologics including two, three and four-chain bispecifics, and requires only small numbers of clones to be screened to reach commercial titers. This allows us to look in more depth at other properties of the molecule, which is essential with these more complex biologics."

Dr. Darrin M Disley, CEO of Horizon Discovery Group plc, commented: ďHorizonís CHO SOURCE platform continues to challenge commercial and technical expectations in the industry. Horizonís GS Knockout cell line has undergone extensive validation to demonstrate its suitability for biomanufacturing, and by including ATUMís powerful expression vector we are now able to offer customers an improved solution.Ē


ENDS


Media contacts:

For Horizon Discovery Group plc:
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

For ATUM:
Lisa Lilienthal, 404-661-3679
lisa@iconatl.com


About ATUM

ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUMís tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster. The company is privately held and is headquartered in Newark, California. For more information, please visit https://www.atum.bio.


About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizonís core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN, CRISPR and Transposon) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizonís commercial offering has been adopted by over 1,600 unique research organizations in over 50 countries as well as in the Companyís own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalized basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchangeís AIM market under the ticker ďHZDĒ.

   
Record changed: 2017-06-06

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Horizon Discovery (Group)


To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com Ė The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px